DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))

 phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))

 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))

 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))

 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))

 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))

 phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))

 phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))

 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))

 phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))

 phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))

 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2))

 phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2))

 DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2))